Barclays Analysts Give Fresenius SE & Co KGaA (FRE) a €81.00 Price Target

Barclays set a €81.00 ($100.00) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research note issued to investors on Friday morning. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also recently commented on FRE. Citigroup set a €83.00 ($102.47) target price on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Thursday, October 19th. Goldman Sachs Group set a €78.00 ($96.30) target price on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Tuesday, October 31st. Warburg Research set a €80.00 ($98.77) target price on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Thursday, December 21st. Bank of America set a €75.00 ($92.59) target price on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Monday, November 6th. Finally, Kepler Capital Markets set a €63.00 ($77.78) target price on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Tuesday, November 28th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of €78.80 ($97.28).

Fresenius SE & Co KGaA (FRE) opened at €65.58 ($80.96) on Friday. The company has a market cap of $36,440.00 and a price-to-earnings ratio of 20.89. Fresenius SE & Co KGaA has a 1-year low of €60.16 ($74.27) and a 1-year high of €80.00 ($98.77).

ILLEGAL ACTIVITY WARNING: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/06/barclays-analysts-give-fresenius-se-81-00-price-target.html.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply